First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

Detalles Bibliográficos
Autor principal: Hafner, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648794/
https://www.ncbi.nlm.nih.gov/pubmed/34873145
http://dx.doi.org/10.1038/s41392-021-00813-y
_version_ 1784610885924290560
author Hafner, Susanne
author_facet Hafner, Susanne
author_sort Hafner, Susanne
collection PubMed
description
format Online
Article
Text
id pubmed-8648794
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86487942021-12-22 First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence Hafner, Susanne Signal Transduct Target Ther Research Highlight Nature Publishing Group UK 2021-12-06 /pmc/articles/PMC8648794/ /pubmed/34873145 http://dx.doi.org/10.1038/s41392-021-00813-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Highlight
Hafner, Susanne
First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
title First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
title_full First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
title_fullStr First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
title_full_unstemmed First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
title_short First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
title_sort first-line anti-vegf plus egfr-tki in egfr-mutant nsclc: adding the artemis trial to the puzzle of current evidence
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648794/
https://www.ncbi.nlm.nih.gov/pubmed/34873145
http://dx.doi.org/10.1038/s41392-021-00813-y
work_keys_str_mv AT hafnersusanne firstlineantivegfplusegfrtkiinegfrmutantnsclcaddingtheartemistrialtothepuzzleofcurrentevidence

Ejemplares similares